Skin infection

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Retrieved on: 
Tuesday, March 21, 2023
Inflammation, Skin infection, Siliceous ooze, Civil service commission, Regeneron Pharmaceuticals, Parent, Overalls, Quality of life, Atopic dermatitis, Arthralgia, GPER, TCS, Pain, Heart, European Commission, Patient, Risk, Child, Biological soil crust, European, International development, Growth, Infant, Immunology, Ageing, MPH, Conjunctivitis, EC, Red, Human, Eosinophilia, Skin, Caregiver, Safety, Conditional sentence, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Copper, EU, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.

Key Points: 
  • “I’ve personally witnessed how this chronic skin disease can disrupt the lives of entire families when left uncontrolled.
  • Between 85% and 90% of patients first develop symptoms before 5 years of age, which can often continue through adulthood.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • “Too often the parents and caregivers of children with severe atopic dermatitis are left desperate for new treatments to manage this chronic disease.

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 

Retrieved on: 
Tuesday, March 21, 2023
Skin infection, Siliceous ooze, Parent, Overalls, Quality of life, Atopic dermatitis, Arthralgia, European Commission, TCS, Pain, Patient, Risk, Child, Biological soil crust, European, Growth, Infant, Ageing, Conjunctivitis, EC, Red, Human, Eosinophilia, Skin, Caregiver, Safety, Conditional sentence, Disease, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Copper, EU, Dupilumab

The European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.

Key Points: 
  • The European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • With this latest approval, Dupixent is the first-ever biologic medicine for people living with atopic dermatitis from infancy to adulthood.
  • Too often the parents and caregivers of children with severe atopic dermatitis are left desperate for new treatments to manage this chronic disease.

BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs

Retrieved on: 
Wednesday, March 8, 2023
Woman, Catherine Disher, Science, Medication, NYSE, Injection, Xerostomia, Partnership, Allergy, FAAD, International Women's Day, Senior, Weakness, Paratriathlon, Headache, ALS, Medical director, Risk, Official rules of Major League Baseball, MATCH International Women's Fund, AB toxin, Asthma, Vitamin, Fatigue, Myasthenia gravis, Wheeze, Rash, Skin infection, Dermatology, Breast milk, Lambert–Eaton myasthenic syndrome, Skin, ABBV, AbbVie, Growth, Success, Face, Neck pain, Hope, Human, Eyelid, Eyebrow, Pain, Dizziness, Management, Nursing, Pharmaceutical industry, Birth control, Canning, Cosmetics, Medical device, MD

IRVINE, Calif., March 8, 2023 /PRNewswire/ -- In honor of International Women's Day, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced that BOTOX® Cosmetic is partnering with IFundWomen, the go-to funding marketplace for women-owned businesses, on a grant program. Women entrepreneurs can apply for the opportunity to receive one of 20 grants worth $25,000 each, as well as a year of coaching and mentorship to boost confidence, advance knowledge, and inspire action.

Key Points: 
  • The goal of the partnership is to help address the "Confidence Gap" among rising women entrepreneurs.
  • "Success depends as much on confidence as it does on competence," said Karen Cahn, Founder, and Chief Executive Officer of IFundWomen.
  • "Despite the many advancements women entrepreneurs have made because of their high levels of competence, the 'Confidence Gap' still very much exists.
  • With BOTOX® Cosmetic and IFundWomen, the opportunity for grants, coaching, and mentorship help make that path more straightforward for women entrepreneurs."

Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis

Retrieved on: 
Friday, January 27, 2023
European Directive on Traditional Herbal Medicinal Products, Food, Safety, Conjunctivitis, Red, European Commission, Eosinophilia, Caregiver, Quality of life, Risk, CHMP, Patient, Union, Skin, Regulation of tobacco by the U.S. Food and Drug Administration, TCS, Atopic dermatitis, Regeneron Pharmaceuticals, Siliceous ooze, European Medicines Agency, Growth, Biological soil crust, Skin infection, Pain, Birth control, Vaccine, EU, Sanofi, Lancet, Dupilumab

TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent® (dupilumab), recommending expanded approval in the European Union (EU) to treat severe atopic dermatitis in children 6 months to 5 years old who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In June 2022, Dupixent was approved by the U.S. Food and Drug Administration for children in this age group.

Key Points: 
  • The European Commission is expected to announce a final decision on the Dupixent application in the coming months.
  • In June 2022, Dupixent was approved by the U.S. Food and Drug Administration for children in this age group.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • The use of Dupixent in infants and young children less than 6 years of age with severe atopic dermatitis is investigational in the EU and is not yet approved.

Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

Retrieved on: 
Friday, January 27, 2023
European Directive on Traditional Herbal Medicinal Products, Food, Safety, Conjunctivitis, Red, European Commission, Eosinophilia, Caregiver, Quality of life, Risk, CHMP, Patient, Union, Skin, Regulation of tobacco by the U.S. Food and Drug Administration, TCS, Atopic dermatitis, Siliceous ooze, European Medicines Agency, Growth, Biological soil crust, Skin infection, Pain, Birth control, Vaccine, EU, Lancet, Dupilumab

The European Commission is expected to announce a final decision on the Dupixent application in the coming months.

Key Points: 
  • The European Commission is expected to announce a final decision on the Dupixent application in the coming months.
  • In June 2022, Dupixent was approved by the U.S. Food and Drug Administration for children in this age group.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • The use of Dupixent in infants and young children less than 6 years of age with severe atopic dermatitis is investigational in the EU and is not yet approved.

Global Medical Adhesives Market Set to Reach USD 16.41 Billion by 2031, With a Sustainable CAGR Of 7.6% | Growth Market Reports

Retrieved on: 
Thursday, January 12, 2023
Silicone, ToC, Bleeding, Key, Equipment, Completeness, Patient, Infection, Breathability, Skin infection, Traction, Acrylic, Retail, Online shopping, Adhesive, Birth control, Solid, Growth, Others

Based on application, the global medical adhesives market is segmented into surgery, dental, medical devices & equipment, internal medical applications, external medical applications, and others.

Key Points: 
  • Based on application, the global medical adhesives market is segmented into surgery, dental, medical devices & equipment, internal medical applications, external medical applications, and others.
  • The surgery segment is anticipated to grow at a significant pace in the coming years due to the increasing use of medical adhesives.
  • Based on resin, the medical adhesives market is segregated into acrylic, silicone-based, epoxy, cyanoacrylate, polyurethane, and others.
  • In terms of region, the global medical adhesives market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Global Medical Adhesives Market Set to Reach USD 16.41 Billion by 2031, With a Sustainable CAGR Of 7.6% | Growth Market Reports

Retrieved on: 
Thursday, January 12, 2023
Silicone, ToC, Bleeding, Key, Equipment, Completeness, Patient, Infection, Breathability, Skin infection, Traction, Acrylic, Retail, Online shopping, Adhesive, Birth control, Solid, Growth, Others

Based on application, the global medical adhesives market is segmented into surgery, dental, medical devices & equipment, internal medical applications, external medical applications, and others.

Key Points: 
  • Based on application, the global medical adhesives market is segmented into surgery, dental, medical devices & equipment, internal medical applications, external medical applications, and others.
  • The surgery segment is anticipated to grow at a significant pace in the coming years due to the increasing use of medical adhesives.
  • Based on resin, the medical adhesives market is segregated into acrylic, silicone-based, epoxy, cyanoacrylate, polyurethane, and others.
  • In terms of region, the global medical adhesives market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Merz Aesthetics® Announces Teyana Taylor as New Xeomin® (incobotulinumtoxinA) Brand Partner

Retrieved on: 
Tuesday, November 1, 2022
Music, Other Health, Health, Women, Pharmaceutical, Entertainment, Celebrity, Men, Cosmetics, Retail, Consumer, People, Dizziness, Allergy, Breast milk, Skin infection, A Thousand and One Wives, Medication, Muscle, Color, Water, News, Partnership, Asthma, Time, Family, Risk, Botulism, Merz, Loyalty program, Rash, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Merz Aesthetics Women's Challenger, Wheeze, Muscle weakness, Human, Safety, Injection, Beauty, Red, Swelling, Food, Medicine, Woman, FDA, Catherine Disher, Patient, Man, Multimedia, Music, Paramount Pictures, Skin care, Female, Eyebrow, Vitamin, Cosmetics, Health insurance, Pharmaceutical industry, Canning, Birth control, Toxin (comics), Toxin (comics)

Merz Aesthetics, the worlds largest dedicated medical aesthetics business, today announced Teyana Taylor as the latest Xeomin (incobotulinumtoxinA) brand partner.

Key Points: 
  • Merz Aesthetics, the worlds largest dedicated medical aesthetics business, today announced Teyana Taylor as the latest Xeomin (incobotulinumtoxinA) brand partner.
  • View the full release here: https://www.businesswire.com/news/home/20221101005084/en/
    Merz Aesthetics announces Teyana Taylor as new Xeomin (incobotulinumtoxinA) brand partner (Photo: Business Wire)
    I always strive to understand the ingredients in any product Im using and listen to trusted sources like my doctors when choosing whats right for my specific skin type, said 31-year-old Taylor.
  • The announcement of Taylor as the newest Xeomin brand partner is a part of the Beauty on Your Terms multi-channel campaign from Merz Aesthetics, which empowers women and men to embrace beauty on their own terms.
  • Teyana Taylor embodies the true meaning of Beauty on Your Terms through her music, her style and, now, her beauty treatments, said Patrick Urban, Merz Aesthetics President, North America.

Global Antifungal Agents Market Report 2022: Rising Incidences of Fungal Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022
Health, Other Health, MSD, Skin infection, CDC, Pandion, Laboratory, Aspergillosis, Therapy, Growth, Abbott Laboratories, Antifungal, Pfizer, CAGR, Bayer, Patient, Fungus, Mycosis, Surgeon, Watchlist, Powder, Azole, World Health Organization, Infection, Partnership, WHO, Candidiasis, Center, World, Acquisition, Dermatophytosis, Africa Centres for Disease Control and Prevention, Joint Medical Service (Germany), Pathogenic fungus, Tinea versicolor, Bacteria, Death, Tablet, Canker, Polyene, Vaccine, Pharmaceutical industry, Merck, Echinocandin, Allylamine

The global antifungal agents market is anticipated to grow at a significant CAGR of nearly 3.5% during the forecast period.

Key Points: 
  • The global antifungal agents market is anticipated to grow at a significant CAGR of nearly 3.5% during the forecast period.
  • Antifungal agents prevent and destroy the growth of fungi that are responsible for several diseases such as aspergillosis, ringworm, and skin infection, among others.
  • Antifungal agents are a class of drugs that are used to detect and eliminate fungal infections from the body with minimal side effects.
  • Another major factor contributing to the growth of the market is the rising incidences of fungal diseases.

Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

Retrieved on: 
Monday, October 3, 2022
Lip, History, Toxin (comics), Anaphylaxis, Lists of diseases, Safety, Pimple, Warfarin, Skin discoloration, Allergy, Swelling, Vitamin, Coagulopathy, Cheek, Victory Unintentional, Myasthenia gravis, Skin, Bleeding, Face, Rash, Upper respiratory tract infection, Recurrence, Headache, Skin infection, Lidocaine, Human, Patient, Severe cognitive impairment, Infection, Blood, Nausea, Bruise, ALS, Inflammation, Muscle, Amyotrophic lateral sclerosis, Red, Medication, Restylane, Aspirin, Muscle weakness, Nose, Tenderness, Wound, Multimedia, Pain, FDA, Herbal, Cyst, Vascular occlusion, Risk, Scar, Bacteria, Hypertrophic scar, Stroke, Sculptra, Catherine Disher, Infarction, Death, Hyaluronic acid, Eyebrow, Laser, Galderma, Use, Cosmetics, Canning, Birth control, Dietary supplement, Pharmaceutical industry, Medicine, Tissue paper, Botulinum toxin

These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.

Key Points: 
  • These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.
  • Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products.
  • Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete.
  • Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area.